Published in Clin Cancer Res on April 10, 2015
The kinome 'at large' in cancer. Nat Rev Cancer (2016) 0.88
PubChem BioAssay: 2017 update. Nucleic Acids Res (2016) 0.84
Future directions in the treatment of osteosarcoma. Curr Opin Pediatr (2016) 0.79
Aberrant expression of microRNA-99a and its target gene mTOR associated with malignant progression and poor prognosis in patients with osteosarcoma. Onco Targets Ther (2016) 0.79
MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. Genes Cancer (2015) 0.77
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. F1000Res (2016) 0.75
Deciphering signaling networks in osteosarcoma pathobiology. Exp Biol Med (Maywood) (2016) 0.75
Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. Elife (2016) 0.75
Downregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway. Onco Targets Ther (2017) 0.75
Blocking fatty acid synthase inhibits tumor progression of human osteosarcoma by regulating the human epidermal growth factor receptor 2/phosphoinositide 3-kinase/protein kinase B signaling pathway in xenograft models. Exp Ther Med (2017) 0.75
The spliceosome: design principles of a dynamic RNP machine. Cell (2009) 12.82
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer (2009) 6.00
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol (2005) 5.55
Microarrays of cells expressing defined cDNAs. Nature (2001) 5.05
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol (2007) 4.95
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature (2003) 3.25
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 2.74
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
An alternative splicing network links cell-cycle control to apoptosis. Cell (2010) 2.43
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep (2014) 2.27
A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol (2014) 2.17
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med (2013) 1.98
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A (2008) 1.98
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett (2010) 1.89
A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma (2012) 1.86
An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes Dev (2014) 1.73
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett (2013) 1.72
Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell (2013) 1.72
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.55
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res (2003) 1.52
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet (2003) 1.49
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A (2014) 1.36
Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer (2012) 1.33
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev (2013) 1.31
Translational control of TOP2A influences doxorubicin efficacy. Mol Cell Biol (2011) 1.25
Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res (2014) 1.23
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol (2010) 1.22
The bHLH regulator pMesogenin1 is required for maturation and segmentation of paraxial mesoderm. Genes Dev (2000) 1.22
Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res (2011) 1.21
A blueprint for advancing genetics-based cancer therapy. Cell (2011) 1.16
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 1.15
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep (2014) 1.09
The Wnt3a/β-catenin target gene Mesogenin1 controls the segmentation clock by activating a Notch signalling program. Nat Commun (2011) 1.07
Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. Bone (2013) 1.01
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.00
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95
NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett (2013) 0.94
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer (2014) 0.94
Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med Genomics (2014) 0.88
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.86